PSquared Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

PSquared Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,536,316	Closed	-$282M	–	14
2021 Q2	$282M	Buy	1,536,316 +55,893	+4%	+$9.59M	20.25%	2
2021 Q1	$226M	Buy	+1,480,423	New	+$229M	19.57%	2

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

PSquared Asset Management's ALXN Position: Q3 2021 in Review

PSquared Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,536,316 shares — an estimated $282M sold.

PSquared Asset Management first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $282M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

PSquared Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
PSquared Asset Management sold 1,536,316 Alexion Pharmaceuticals shares in Q3 2021, an estimated $282M.
PSquared Asset Management first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
PSquared Asset Management's Alexion Pharmaceuticals position peaked at $282M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on PSquared Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.